Use of inhaled anticholinergics in australia
- At: 2014 FIP Congress in Bangkok (Thailand)
- Type: Poster
- By: KHANAL, Saval (The University of Queensland, School of Pharmacy, Woolloongabba, qld, Australia)
- Co-author(s): Nissen, Lisa (School of Clinical Sciences, Queensland University of Technology,, Brisbane, Australia)
Veerman, Lennert (School of Population Health, The University of Queensland, Australia, Brisbane, Australia)
Hollingworth, Samantha (School of Pharmacy, The University of Queensland, Brisbane, Australia)
Background: In Australia, 1.45 million people live with some form of chronic obstructive pulmonary diseases (COPD). Inhaled anticholinergics (ipratropium, tiotropium) are important medicines for persistent symptoms of COPD.
Aims: To evaluate the use of inhaled anticholinergics from 2005 to 2010 in an Australian general practice (GP) database and.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.